1

Welcome and role call

BGO, all

2

 Allergy/hypersensitivity editorial guidelines

BGO

• Editorial guidelines based on approved model for review

Guidelines reviewed. Few additional edits suggested. Document below represents the final version:

Hypersensitivity+allergy modeling guidelines_v2.docx

3

Intolerance to substance

BGO

• Associating substance

Due to difficulty in precisely defining an intolerance pathological process, decision made to relate substance to intolerance propensity by use of associated with role. Editorial guidelines incorporated into above Hypersensitivity + allergy document

https://snomed.atlassian.net/browse/IHTSDO-712

4

Complications and sequela

BGO

• Editorial guidelines review

Revised guidelines with edits by @Phil Brown and @Bruce Goldberg reviewed and approved. Final document posted below:

Modelling_of_Complications_Sequela_v9.docx

5

During and/or after

BGO

• Should the proposed during and/or after role be used for all procedure complications for which a temporal relationship is not specified?

• Consensus was that for combined disorders/disorders with procedures for which a temporal sequence was not specified between components to not use during and/or after.

• @Bruce Goldberg to clarify with @Ed Cheetham initial use case for this proposed role

6

 Follow-up from London April business meeting

BGO

•  Device associated infections

Decision reached to continue to model device infections using associated with role

7

Modeling of CVAs due to thrombosis/embolus - follow-up

BGO

• Revised model for review

• Proposed model was to use specific artery/vein thrombosis concepts as value of due to along with an associated morphology of 78195007 |Occlusive thrombus (morphologic abnormality)|. Issue raised that occlusive thrombus specifically refers to the cause (specific artery/vein thrombosis) rather than the CVA. Suggested soultion is to create specific occlusive artery/vein thrombosis concepts as the value of due to

• @Bruce Goldberg to test above in SCA tool
  
  

8

AOB, adjourn

ALL

• Next meeting July 10, 2017 2100 UTC